These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 6865444)
21. Secretions of adrenal medulla and cortex after electrical stimulation of amygdala. Ishihara I; Komori Y; Tamura Y Annu Rep Res Inst Environ Med Nagoya Univ; 1964; 13():21-30. PubMed ID: 5876916 [No Abstract] [Full Text] [Related]
22. Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models. Nagata S; Takeyama K; Fukuya F; Nagai R; Hosoki K; Nishimura K; Deguchi T; Karasawa T Arzneimittelforschung; 1995 Aug; 45(8):853-8. PubMed ID: 7575746 [TBL] [Abstract][Full Text] [Related]
23. Mechanism of the antagonism of the hypotensive action of guanethidine by propranolol. Grewal RS; Kaul CL Br J Pharmacol; 1970 Apr; 38(4):771-5. PubMed ID: 5441789 [TBL] [Abstract][Full Text] [Related]
24. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 3rd communication: antihypertensive effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3-b] pyridine-5-carboxylate in hypertensive rats and dogs. Ueda M; Matsumura S; Masui M; Matsuura E; Kawakami M; Fujitomo H; Umeda T; Kagawa H; Hirohata S; Shima K Arzneimittelforschung; 1993 Dec; 43(12):1282-90. PubMed ID: 8141815 [TBL] [Abstract][Full Text] [Related]
25. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure. Jackson EK; Dubinion JH; Mi Z Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624 [TBL] [Abstract][Full Text] [Related]
26. Cardiovascular effects of a novel vasoactive antihypertensive agent, Ro 12-4713. Gerold M; Eigenmann R; Hefti F; Daum A; Haeusler G J Pharmacol Exp Ther; 1981 Mar; 216(3):624-33. PubMed ID: 7009831 [TBL] [Abstract][Full Text] [Related]
27. [Effect of bromocriptine on arterial blood pressure and serum prolactin level in patients with essential arterial hypertension]. Hudziak G; Kuska J Kardiol Pol; 1988; 31 Suppl 1():22-9. PubMed ID: 3221620 [No Abstract] [Full Text] [Related]
28. Effects of adrenolytic drugs on the antihypertensive action of beta-blocking agents in the acute neurogenic hypertensive dog. Montastruc JL; Morales-Olivas F; Montastruc P J Pharmacol; 1981; 12(4):427-39. PubMed ID: 7321572 [TBL] [Abstract][Full Text] [Related]
30. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent. Prichard BN; Owens CW; Graham BR J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737 [TBL] [Abstract][Full Text] [Related]
31. [Influence of nephrectomy on the antihypertensive effects of propranolol in the dog (author's transl)]. Montastruc JL; Gaillard-Plaza G; Thomas J; Montastruc P J Pharmacol; 1981; 12(4):465-70. PubMed ID: 7321575 [TBL] [Abstract][Full Text] [Related]
32. Dopaminergic mechanisms and genetic factors in blood pressure regulation. Golda V; Petr R Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl; 1982; 25(5):419-27. PubMed ID: 6985385 [No Abstract] [Full Text] [Related]
33. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment]. Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399 [TBL] [Abstract][Full Text] [Related]
34. Investigation of the inhibitory effect of N(G)-nitro-L-arginine methyl ester on the antihypertensive effect of the angiotensin AT1 receptor antagonist, GR138950. Anderson IK; Drew GM Br J Pharmacol; 1997 Dec; 122(7):1385-94. PubMed ID: 9421286 [TBL] [Abstract][Full Text] [Related]
35. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. de Champlain J; Karas M; Nguyen P; Cartier P; Wistaff R; Toal CB; Nadeau R; Larochelle P J Hypertens; 1998 Sep; 16(9):1357-69. PubMed ID: 9746123 [TBL] [Abstract][Full Text] [Related]
36. A new ATP-sensitive potassium channel opener reduces blood pressure and reverses cardiovascular remodeling in experimental hypertension. Wang H; Long CL; Zhang YL J Pharmacol Exp Ther; 2005 Mar; 312(3):1326-33. PubMed ID: 15525792 [TBL] [Abstract][Full Text] [Related]